Lilly Adds Gene Delivery Technology to CAR T in up to $7B Kelonia Deal

Why It Matters

The acquisition gives Lilly a rare in‑vivo CAR‑T capability, positioning it to lead a next‑generation cell‑therapy market while leveraging its strong balance sheet for high‑risk innovation. It also signals a broader wave of biopharma M&A as majors chase genetic‑medicine platforms.

Key Takeaways

• Lilly to acquire Kelonia for up to $7 B, adding iGPS platform
• iGPS enables in‑vivo lentiviral CAR‑T, bypassing manufacturing
• KLN‑1010 targets multiple myeloma; early data shows tolerability
• Deal complements Lilly’s 2026 $2.4 B Orna CAR‑T acquisition
• Analysts expect more big‑pharma M&A as in‑vivo CAR‑T gains traction

Pulse Analysis

Eli Lilly’s decision to acquire Kelonia Therapeutics for up to $7 billion marks a decisive move into in‑vivo CAR‑T therapy, a technology that could sidestep the costly ex‑vivo cell manufacturing that dominates today’s market. Kelonia’s iGPS platform uses lentiviral particles to deliver CAR‑encoding genes directly to a patient’s T‑cells, allowing the body to produce its own engineered cells. If the approach scales, it promises faster treatment timelines, lower production overhead, and broader applicability across hematologic malignancies and potentially solid tumors.

The transaction follows Lilly’s $2.4 billion purchase of Orna Therapeutics in February and a $6.3 billion buyout of Centessa, underscoring an aggressive M&A strategy aimed at diversifying beyond small‑molecule and antibody franchises. With $3.25 billion paid upfront and milestone‑linked earn‑outs, the deal fits Lilly’s robust cash flow and strong balance sheet, allowing it to fund high‑risk, high‑reward programs. Industry observers anticipate that other majors such as Novartis, Amgen and AbbVie will accelerate similar deals, turning the first quarter of 2026 into a hotbed of biopharma consolidation.

Despite the promise, in‑vivo CAR‑T remains unproven and faces stiff competition from Gilead, AbbVie and Bristol‑Myers Squibb, which are pursuing parallel lentiviral and mRNA delivery routes. Clinical data on KLN‑1010, Kelonia’s anti‑BCMA candidate for multiple myeloma, showed tolerability and early responses at the American Society of Hematology meeting, but larger trials are needed to confirm durability. If successful, Lilly could leverage iGPS across its oncology pipeline, creating a platform‑centric revenue stream and reinforcing its position as a leader in next‑generation cell therapies.